Forte Biosciences (FBRX) Accumulated Expenses (2016 - 2026)

Forte Biosciences (FBRX) has reported Accumulated Expenses for 11 consecutive years, with $10.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 745.04% year-over-year to $10.6 million; the TTM figure through Mar 2026 stood at $10.6 million (up 745.04% YoY), while the FY2025 annual figure was $2.2 million, up 45.07% from the prior year.
• Accumulated Expenses rose to $10.6 million in Q1 2026 per FBRX's latest filing, from $2.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $10.6 million in Q1 2026 and bottomed at $359000.0 in Q1 2022.
• Historically, Accumulated Expenses has averaged $2.2 million across 5 years, with a median of $1.6 million in 2024.
• Annual changes were most pronounced in 2022 — Accumulated Expenses tumbled 77.22% — and 2026, when it jumped 745.04%.
• Forte Biosciences' Accumulated Expenses stood at $2.0 million in 2022, then tumbled by 53.26% to $947000.0 in 2023, then jumped by 63.78% to $1.6 million in 2024, then jumped by 45.07% to $2.2 million in 2025, then jumped by 369.47% to $10.6 million in 2026.
• Business Quant data shows FBRX's Accumulated Expenses at $10.6 million in Q1 2026, $2.2 million in Q4 2025, and $1.3 million in Q3 2025.